---
title: "CSC Financial Sticks to Its Buy Rating for Hansoh Pharmaceutical Group Company Limited (3692)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283318316.md"
description: "In a report released yesterday, from CSC Financial maintained a Buy rating on Hansoh Pharmaceutical Group Company Limited, with a price target of HK$48.73.Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Strong Buy analyst consensus rating for Hansoh Pharmaceutical Group Company Limited with a HK$46.26 average price target."
datetime: "2026-04-20T08:25:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283318316.md)
  - [en](https://longbridge.com/en/news/283318316.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283318316.md)
---

# CSC Financial Sticks to Its Buy Rating for Hansoh Pharmaceutical Group Company Limited (3692)

In a report released yesterday, from CSC Financial maintained a Buy rating on Hansoh Pharmaceutical Group Company Limited, with a price target of HK$48.73.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Hansoh Pharmaceutical Group Company Limited with a HK$46.26 average price target.

### Related Stocks

- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)
- [06066.HK](https://longbridge.com/en/quote/06066.HK.md)
- [601066.CN](https://longbridge.com/en/quote/601066.CN.md)

## Related News & Research

- [Hansoh Pharma Wins NMPA Nod for Trial of New KRAS-Targeting Cancer Drug](https://longbridge.com/en/news/286266501.md)
- [Hansoh Pharmaceutical Wins Breakthrough Therapy Status for Esophageal Cancer ADC](https://longbridge.com/en/news/285857826.md)
- [Goldman Sachs Reaffirms Their Buy Rating on Prudential (PRU)](https://longbridge.com/en/news/286866728.md)
- [A Look At Hansoh Pharmaceutical Group’s Valuation As XINYUE Gains Third Rare Disease Approval In China](https://longbridge.com/en/news/282920469.md)
- [Hansoh Pharmaceutical to Raise HK$4.68 Billion via Zero-Coupon Convertible Bonds](https://longbridge.com/en/news/273753448.md)